Your browser is no longer supported. Please, upgrade your browser.
Settings
AMGN Amgen Inc. daily Stock Chart
AMGN [NASD]
Amgen Inc.
IndexS&P 500 P/E14.33 EPS (ttm)10.01 Insider Own0.13% Shs Outstand747.00M Perf Week-0.39%
Market Cap107.16B Forward P/E11.45 EPS next Y12.53 Insider Trans-0.30% Shs Float741.71M Perf Month-1.37%
Income7.59B PEG1.90 EPS next Q2.80 Inst Own79.90% Short Float1.05% Perf Quarter-16.05%
Sales22.56B P/S4.75 EPS this Y35.20% Inst Trans-1.89% Short Ratio2.01 Perf Half Y-5.11%
Book/sh41.20 P/B3.48 EPS next Y8.37% ROA10.10% Target Price182.21 Perf Year-7.79%
Cash/sh50.84 P/C2.82 EPS next 5Y7.52% ROE25.80% 52W Range132.74 - 175.66 Perf YTD-9.30%
Dividend4.00 P/FCF379.99 EPS past 5Y13.60% ROI12.50% 52W High-18.34% Beta1.16
Dividend %2.79% Quick Ratio4.10 Sales past 5Y7.60% Gross Margin81.50% 52W Low8.07% ATR3.28
Employees17900 Current Ratio4.30 Sales Q/Q1.50% Oper. Margin41.40% RSI (14)43.78 Volatility2.04% 1.83%
OptionableYes Debt/Eq1.15 EPS Q/Q9.80% Profit Margin33.60% Rel Volume1.20 Prev Close140.59
ShortableYes LT Debt/Eq0.99 EarningsOct 27 Payout37.50% Avg Volume3.87M Price143.45
Recom2.40 SMA20-1.27% SMA50-5.24% SMA200-8.05% Volume4,637,687 Change2.03%
Nov-08-16Initiated Mizuho Buy $164
Aug-26-16Initiated Gabelli & Co Hold
Jun-29-16Initiated Bernstein Mkt Perform
Feb-25-16Initiated Citigroup Neutral $165
Feb-08-16Reiterated Argus Buy $202 → $185
Jan-20-16Initiated Credit Suisse Outperform $205
Dec-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-04-15Initiated Wells Fargo Market Perform
Oct-29-15Reiterated UBS Buy $168 → $180
Sep-01-15Initiated Raymond James Mkt Perform
Jul-31-15Reiterated RBC Capital Mkts Outperform $185 → $190
Jul-31-15Reiterated Deutsche Bank Buy $192 → $195
Jul-31-15Reiterated Barclays Equal Weight $180 → $185
May-28-15Reiterated Deutsche Bank Buy $200 → $192
Apr-22-15Reiterated UBS Buy $175 → $185
Apr-22-15Reiterated RBC Capital Mkts Outperform $178 → $185
Oct-29-14Reiterated Argus Buy $140 → $185
Oct-28-14Reiterated RBC Capital Mkts Outperform $150 → $165
Sep-08-14Reiterated RBC Capital Mkts Outperform $138 → $150
Aug-04-14Reiterated Argus Buy $135 → $140
Dec-10-16 09:42AM  Will Trump Break With Republicans And Push Major Drug Price Reform?
Dec-09-16 05:15PM  Week in Review: Dow Scores Five Straight Days of Record Closes
04:53PM  Amgen and Broadcom climb; Restoration Hardware falls
04:04PM  Dow, in Another Record Close, Ends With Weekly Gains for Fifth Consecutive Week
12:08PM  3 Hot and Undervalued Biotechs That Are Immune to Trump's Threats
11:39AM  Stocks Hold at Records as Health Care Jumps, Crude Surges
Dec-07-16 02:45PM  Trump Vow On Drug Prices Fails To Stop Rally; Apple Retakes Prior Buy Point
02:44PM  4 Stocks Set for Dividend Hikes Next Week at Barrons.com
10:52AM  Dividend-paying stocks pull US indexes up; drugmakers drop
08:49AM  Biotech Stock Roundup: Actelion Remains in M&A Spotlight, ASH Data in Focus
08:18AM  Better Buy: Amgen Inc. vs. Pfizer at Motley Fool
Dec-06-16 04:31PM  Rivals Kite Pharma, Juno Therapeutics Tank On Cancer Data; Spark Flies
Dec-05-16 03:55PM  Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell
11:43AM  Amgen Rolls Out Kidney Disease Campaign (AMGN) at Investopedia
09:36AM  Amgen/Allergan File for EU Approval of Avastin Biosimilar
08:47AM  Amgen, Allergan File for Avastin Biosimilar in EU (AGN) at Investopedia
Dec-04-16 01:13PM  Acceleron, Celgene Seek to Replace Entrenched Anti-Anemia Drugs in MDS Treatment
08:27AM  3 Large-Cap Stocks to Buy in December at Motley Fool
05:37AM  5 Dividend Stocks to Buy in December at Motley Fool
Dec-02-16 04:16PM  Here's How Much Trump Tax Cuts Could Boost The Stock Market
04:05PM  Amgen, Regeneron 2017 LDL-Busters Could Boost This Small-Cap Biotech
04:00PM  Amgen Announces Launch Of Blood Counts And Collaboration With StoryCorps To Record And Share Stories Of Those Impacted By Multiple Myeloma PR Newswire
09:53AM  Allergan & Amgen Looking for Approvals (AGN, AMGN) at Investopedia
09:33AM  Amgen, Allergan apply for European nod for Avastin biosimilar Reuters
09:00AM  Amgen And Allergan Submit Biosimilar Marketing Authorization Application To European Medicines Agency For ABP 215, A Biosimilar Candidate To Bevacizumab PR Newswire
Dec-01-16 05:00PM  Bluebird Rockets On Myeloma Drug; Celgene Gets Boost
04:00PM  Amgen To Present At The Citi 2016 Global Healthcare Conference PR Newswire
02:46PM  Cytokinetics Gets $27M Milestone from Amgen (AMGN, CYTK) at Investopedia
09:40AM  Bluebird Bio, Celgene Multiple Myeloma Therapy Strong In 9-Patient Study
Nov-30-16 10:08PM  The Big Shorts Michael Burry Reveals His New Stock Picks at Insider Monkey
06:31PM  The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv Mecarbil Significantly Improved Cardiac Function In Patients With Chronic Heart Failure PR Newswire
06:30PM  The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv Mecarbil Significantly Improved Cardiac Function in Patients With Chronic Heart Failure GlobeNewswire
12:24PM  Here's Why Arrowhead Pharmaceuticals Inc. Is Being Obliterated Today at Motley Fool
10:00AM  Amgen Announces Presentation Of New Data In Acute Lymphoblastic Leukemia, Multiple Myeloma And Immune Thrombocytopenia At ASH 2016 PR Newswire
09:33AM  Better Buy: Biogen Inc. vs. Amgen at Motley Fool
08:38AM  Pfizer/Merck KGaA: Priority Review for Cancer Drug Avelumab
Nov-29-16 07:11PM  Cramer's lightning round: Stocks down so low with a flashing buy signal at CNBC
07:00PM  Cramer Remix: why you shouldnt sell before year end
05:04PM  Falling Revenue in Allergans US General Medicines Segment
03:04PM  Allergans US Specialized Therapeutics Segment in 3Q16
02:00PM  AbbVies Financial Guidance for 2017
08:03AM  3 Top Dividend Stocks to Buy in 2017 at Motley Fool
07:00AM  [$$] 'Brain training' healthcare digital games target dementia at Financial Times
Nov-28-16 10:05AM  Humira Has Been a Key Growth Driver for AbbVie in 2016
07:35AM  Short Sellers Grow More Aggressive on Major Biotechs
Nov-25-16 08:04AM  Key Investor Insights into Eli Lillys Recent Developments
Nov-24-16 08:37AM  The 3 Best Dividend Growth ETFs for 2017 at Forbes
Nov-23-16 04:43PM  Is Amgen, Inc. (AMGN) A Good Stock To Buy Now? at Insider Monkey
10:29AM  5 Biotech Stocks George Soros Is Buying at Motley Fool
Nov-22-16 06:30PM  6 Worthy Dividend Stocks Down 10% or More
04:53PM  Alder Keels For Sixth Day After EU Upholds Teva Migraine Patent
03:04PM  Understanding Eli Lillys Business Segments by 3Q16 Performance
09:40AM  Jefferies Makes Another Huge Addition to Franchise Picks Stocks Portfolio at 24/7 Wall St.
08:08AM  J&J Immunotherapy Darzalex OK'd for Label Expansion by FDA
08:05AM  SD-809 Could Be a Strong Growth Driver for Teva Pharmaceutical
Nov-21-16 04:07PM  Amgen, Biogen, Celgene Eye M&A In Trump's 'Pro-Biotech' World
04:06PM  Big Stock Buyback Boost Coming From Trump Tax Proposal: Goldman Sachs
10:50AM  The Positive Performance of the Healthcare Sector
09:59AM  Novartis (NVS) Reports Favorable Data on Enbrel Biosimilar
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Cisco, NextEra Energy, AbbVie and eBay
Nov-18-16 05:27PM  Aegerion's Juxtapid Gets Pricing Authorization in Japan
04:42PM  Drugmaker losses pull stocks lower; small-cap surge goes on
01:43PM  Top Research Reports for Cisco, Amgen & NextEra Energy
08:54AM  Novartis/Amgen Migraine Drug Positive in Phase III Study
08:02AM  Regeneron/Sanofi's Praluent CV Outcomes Study to Continue
Nov-17-16 07:27PM  Money in Medicine: The 30 drug and device makers who paid Oregon doctors the most at bizjournals.com
04:18PM  Amgen On Track For 2018 Migraine-Drug Launch, Beating 'Crowded Field'
11:45AM  Amgen Migraine Drug Does Well in Late Study (AMGN) at Investopedia
10:14AM  Amgen's Migraine Drug Hits Primary Endpoint in STRIVE Study
09:05AM  Early movers: WMT, BBY, SJM, SPLS, AMZN, AAPL, GOOGL, FB & more at CNBC
04:50AM  No early win for Sanofi, Regeneron cholesterol drug in study
04:47AM  Amgen, Novartis aim for big, crowded migraine market after new drug data
Nov-16-16 05:47PM  Amgen's migraine drug succeeds in late-stage trial
05:22PM  Is Immunotherapy the Next Hot Industry for Biotech Stock Investors?
05:01PM  Amgen shares tick higher on positive migraine drug study at MarketWatch
04:40PM  Amgen experiment drug reduces migraines in study
04:30PM  Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In Second Phase 3 Study PR Newswire
04:29PM  Medicines Co., Alnylam Split On Amgen-Rivaling Cholesterol-Buster
09:02AM  Amgen Files BLA for Avastin Biosimilar (AMGN, AGN) at Investopedia
08:17AM  Amgen Files for Avastin Biosimilar; Repatha Data Positive
08:12AM  Biotech Stock Roundup: Biotech Stocks Soar on Election Results, Gilead HBV Drug Approved
Nov-15-16 04:28PM  Amgen, Biogen, Eli Lilly Poised To Rocket On 'Most Important Event'
04:00PM  Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 215 To U.S. Food And Drug Administration PR Newswire
12:28PM  Repatha┬« (Evolocumab) Regresses Atherosclerosis In Patients With Coronary Artery Disease PR Newswire
12:07PM  Cholesterol drug shows promise to help reverse heart disease
11:45AM  Amgen cholesterol drug reduces artery-clogging plaque in study
11:45AM  Amgens Repatha Unclogs Arteries in Good Sign for Future Sales at Bloomberg
11:08AM  George Soros: There's More In That 13F Than Emerging Markets at Barrons.com
Nov-14-16 11:45AM  Amgen's Parsabiv Kidney Drug Approved in EU (AMGN) at Investopedia
09:25AM  Amgen Presents Osteoporosis Data; Parsabiv Approved in EU
09:00AM  New 'Ten To Watch' List Highlights Top Amgen Scholars Poised To Impact The Future Of Science And Medicine PR Newswire
08:00AM  4 Trade Ideas for Amgen
Nov-13-16 07:45AM  3 Drugmakers That Probably Have Lower Tax Rates Than You Do at Motley Fool
Nov-12-16 04:30PM  Results From Phase 3 BRIDGE Study Show Romosozumab Significantly Increases Bone Mineral Density In Men With Osteoporosis PR Newswire
09:44AM  The Shot Heard Round the World: First Inning of Global Reflation
Nov-11-16 06:04PM  Inside AstraZenecas Revenue Fall in 3Q16
04:00PM  European Commission Approves Parsabiv (etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adults On Hemodialysis PR Newswire
11:45AM  Amgen, Janssen to Begin Myeloma Trial (AMGN, JNJ) at Investopedia
09:35AM  Top Biotech and Health Care Stocks Set to Run on Huge Republican Sweep at 24/7 Wall St.
Nov-10-16 04:31PM  [$$] Cancer Therapeutics Startup DNAtrix Boosts Pipeline Through Licensing Deal at The Wall Street Journal
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. Its principal products also comprise EPOGEN to treat a lower-than-normal number of red blood cells caused by chronic kidney disease (CKD) in patients on dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; Repatha for the treatment of high cholesterol; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. The company's other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc; UCB; Novartis AG; Bayer HealthCare Pharmaceuticals Inc; Advaxis, Inc.; Dr. Reddy's Laboratories Ltd.; and Nuevolution AB. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
de Carbonnel FrancoisDirectorSep 09Option Exercise71.645,000358,20021,171Sep 13 06:21 PM
Such Annette LouiseVP, Finance and CAOAug 02Sale174.593,000523,7587,183Aug 03 08:14 PM
Balachandran MadhavanEVP, OperationsMay 04Sale154.1230,0004,623,62455,996May 05 08:16 PM
BALTIMORE DAVIDDirectorApr 29Sale157.213,312520,68432,350May 03 07:12 PM
BALTIMORE DAVIDDirectorMar 30Option Exercise50.445,000252,20037,350Mar 31 06:01 PM
HERRINGER FRANK CDirectorMar 14Option Exercise50.445,000252,20030,608Mar 16 06:48 PM
COFFMAN VANCE DDirectorMar 09Option Exercise50.445,000252,20043,447Mar 10 06:55 PM
Bradway Robert AChairman, CEO and PresidentMar 02Option Exercise50.4484,0004,236,960447,102Mar 04 06:07 PM
Bradway Robert AChairman, CEO and PresidentMar 02Sale146.4820,0002,929,566383,102Mar 04 06:07 PM